Abstract: a sound control device for pneumatically driven mechanical devices and method of use of said device, the device configured to create a sealed intermediary gas medium between the atmosphere and surfaces of the pneumatically driven mechanical device where vibrational energy is generated and where exhaust flow travels, the sound control device further configured to carry such energy and exhaust away from the source where it may be released into the atmosphere in a quieter manner.

Abstract: Methods, systems, and apparatuses are disclosed for a tamper-resistant collection and retention a chemical sample. In one embodiment, the tamper-resistant system comprises a container operable to collect and retain a chemical sample, a tamper-resistant mechanism operable to disengage at a first chemical sample to allow for a collection of a chemical sample, wherein the tamper-resistant mechanism is operable to record one or more of: a date, a time, and a location, of the chemical sample during the collection of the chemical sample, and wherein the tamper-resistant mechanism is further operable to re-engage and lock after the collection of the chemical sample to resist subsequent chemical samples after the first chemical sampling.

Abstract: Methods, systems, and apparatuses are disclosed for a tamper-resistant collection and retention a chemical sample. In one embodiment, the tamper-resistant system comprises a container operable to collect and retain a chemical sample, a tamper-resistant mechanism operable to disengage at a first chemical sample to allow for a collection of a chemical sample, wherein the tamper-resistant mechanism is operable to record one or more of: a date, a time, and a location, of the chemical sample during the collection of the chemical sample, and wherein the tamper-resistant mechanism is further operable to re-engage and lock after the collection of the chemical sample to resist subsequent chemical samples after the first chemical sampling.

Abstract: Methods, systems, and apparatuses are disclosed for a tamper-resistant collection and retention a chemical sample. In one embodiment, the tamper-resistant system comprises a container operable to collect and retain a chemical sample, a tamper-resistant mechanism operable to disengage at a first chemical sample to allow for a collection of a chemical sample, wherein the tamper-resistant mechanism is operable to record one or more of: a date, a time, and a location, of the chemical sample during the collection of the chemical sample, and wherein the tamper-resistant mechanism is further operable to re-engage and lock after the collection of the chemical sample to resist subsequent chemical samples after the first chemical sampling.

Abstract: Methods, systems, and apparatuses are disclosed for a tamper-resistant collection and retention a chemical sample. In one embodiment, the tamper-resistant system comprises a container operable to collect and retain a chemical sample, a tamper-resistant mechanism operable to disengage at a first chemical sample to allow for a collection of a chemical sample, wherein the tamper-resistant mechanism is operable to record one or more of: a date, a time, and a location, of the chemical sample during the collection of the chemical sample, and wherein the tamper-resistant mechanism is further operable to re-engage and lock after the collection of the chemical sample to resist subsequent chemical samples after the first chemical sampling.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: The present invention provides a method for determining the business rating of a business. The method includes the steps of electronically receiving rating information about the business from a plurality of reviewers; electronically weighting the rating information based on the source of the rating information; and electronically developing a rating score based on the weighted rating information. A non-transitory machine-readable storage medium for determining the business rating of the business is also provided.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Abstract: The present invention provides compounds having formula (I): or pharmaceutically acceptable salts and N-oxides thereof, wherein the subscript m is an integer from 0-4; Ar is an optionally substituted aryl; B is an optionally substituted aryl; L1 is an optionally substituted linking group selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and —CH2N(Ru)X5—; and L2 is a bond or C1-3 alkylene. The compounds act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.